Li Yong, Fu Jianchang, Li Zi-Zi, Zhu Qiufang, Chen Keming, Du Huixiong, Liu Jun, Li Yingqing
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Transl Cancer Res. 2021 May;10(5):2318-2327. doi: 10.21037/tcr-20-2252.
Nuclear factor 90 (NF90), one of the double-stranded RNA binding proteins (DSRBP), is involved in many cellular biological processes, includes cell proliferation, differentiation, angiogenesis, cell cycle and immunity. However, its role in nasopharyngeal carcinoma (NPC), and the significance of expression in clinics, remains unknown. The aim of this study was to uncover the relationship between the NF90 expression by immunohistochemistry (IHC) and clinical outcomes in NPC patients.
We retrospectively detected the NF90 expression in 216 NPC specimens by IHC. The cutoff value of NF90 was evaluated using receiver operating characteristic (ROC) curve, the prognostic value of NF90 in NPC was evaluated by Kaplan-Meier and cox multifactor statistical model.
Elevated expression of NF90 was found in 60.2% (130/216). Positive correlation was found between NF90 expression and clinical stage (P=0.018), T stage (P=0.004), and therapy (P=0.020). Over-expression of NF90 predicted favorable progression-free survival (PFS) (P=0.017) and overall survival (OS) (P<0.001) in NPC. Further analysis suggested that the level of NF90 expression was an independent risk factor in NPC prognosis.
These results demonstrate, for the first time, that decreased expression of NF90 is an independent biomarker of worse prognosis for NPC patients, and is a great potential tool for screening the high-risk population for advanced NPC patients.
核因子90(NF90)是双链RNA结合蛋白(DSRBP)之一,参与许多细胞生物学过程,包括细胞增殖、分化、血管生成、细胞周期和免疫。然而,其在鼻咽癌(NPC)中的作用以及在临床中的表达意义尚不清楚。本研究的目的是通过免疫组织化学(IHC)揭示NPC患者中NF90表达与临床结局之间的关系。
我们通过IHC回顾性检测了216例NPC标本中NF90的表达。使用受试者工作特征(ROC)曲线评估NF90的临界值,通过Kaplan-Meier和cox多因素统计模型评估NF90在NPC中的预后价值。
60.2%(130/216)的标本中发现NF90表达升高。NF90表达与临床分期(P={0.018})、T分期(P={0.004})和治疗(P={0.020})呈正相关。NF90的过表达预示着NPC患者有良好的无进展生存期(PFS)(P={0.017})和总生存期(OS)(P<{0.001})。进一步分析表明,NF90表达水平是NPC预后的独立危险因素。
这些结果首次表明,NF90表达降低是NPC患者预后较差的独立生物标志物,并且是筛查晚期NPC患者高危人群的极具潜力的工具。